Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

GSK plc ADR Stock

Price
Target price
€42.40

€42.40

-3.200%
-1.4
-3.200%
-
 
10:06 / Tradegate WKN: A3DMHS / Symbol: GSK / Name: GSK / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of GSK plc ADR in the next few years
Wizard

GSK plc ADR Stock

GSK plc ADR took a tumble today and lost -€1.400 (-3.200%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc ADR stock. Negative votes have not been in the majority for any criteria for this stock
What does GSK do?

Pros and Cons of GSK plc ADR in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of GSK plc ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
GSK plc ADR -3.200% -3.524% -4.783% 30.357% 4.785% 35.185% -1.573%
Bayer AG ADR 0.000% -3.306% -4.098% 84.252% 32.955% -9.302% -0.847%
Novartis AG -1.040% -1.502% -2.353% 27.019% 10.983% 63.950% 63.950%
Novartis AG ADR -0.760% -1.493% -2.222% 26.923% 11.392% 39.535% 65.829%

Comments

GSK (GSK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Ratings data for GSK provided by MarketBeat
Show more

Royal Bank of Canada 
0
Report Share
09.06.26 Buy -4.50%

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for GSK provided by MarketBeat
Show more

Barclays PLC 
0
Report Share
20.02.26 Sell -16.04%

GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for GSK provided by MarketBeat
Show more

Morgan Stanley 
0
Report Share
14.01.26 Sell -1.85%
Show more
Not a member yet? Sign up for free!

News

Spero Therapeutics Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus, Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D
Spero Therapeutics Q2 Earnings Call Highlights

Key Points

MarketBeat 
0 13.08.26